Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $87000.0.

  • Pliant Therapeutics' Gains from Investment Securities changed N/A to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $44000.0, marking a year-over-year decrease of 9985.4%. This contributed to the annual value of $29.8 million for FY2024, which is N/A changed from last year.
  • Per Pliant Therapeutics' latest filing, its Gains from Investment Securities stood at $87000.0 for Q3 2025.
  • In the past 5 years, Pliant Therapeutics' Gains from Investment Securities ranged from a high of $23.7 million in Q1 2024 and a low of -$914000.0 during Q3 2021
  • Its 5-year average for Gains from Investment Securities is $2.6 million, with a median of $147000.0 in 2022.
  • Per our database at Business Quant, Pliant Therapeutics' Gains from Investment Securities skyrocketed by 20393.87% in 2022 and then crashed by 13863.16% in 2023.
  • Pliant Therapeutics' Gains from Investment Securities (Quarter) stood at $844000.0 in 2021, then grew by 12.56% to $950000.0 in 2022, then tumbled by 61.37% to $367000.0 in 2023, then soared by 1556.95% to $6.1 million in 2024, then tumbled by 98.57% to $87000.0 in 2025.
  • Its Gains from Investment Securities stands at $87000.0 for Q3 2025, versus -$35000.0 for Q2 2025 and -$8000.0 for Q1 2025.